GlassScriptPhysician profile
Mark M Tsuchiyose
NPI 1063412195
$32,383.50
in general payments reported to CMS, 2019-2025
31 companies · $2,048 in 2025
The $2,048 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,873 · 2021: $8,191 · 2022: $1,962 · 2023: $1,606 · 2024: $1,273 · 2025: $2,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,749 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,749.45 |
| Education | $177.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,958.03 | 2019-2025 | Linzess, Creon, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,022.71 | 2019-2025 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $2,125.24 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Gilead Sciences, INC. | $1,756.11 | 2019-2025 | Vemlidy |
| Janssen Biotech, INC. | $766.38 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $673.93 | 2019-2025 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $448.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $283.55 | 2019-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $274.79 | 2024-2025 | Zenpep, Vowst |
| Braintree Laboratories, INC. | $265.16 | 2019-2025 | Suflave, Sutab |
| Daiichi Sankyo INC. | $235.60 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $230.67 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $201.03 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $199.48 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $173.43 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $170.20 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Ferring Pharmaceuticals INC. | $86.13 | 2019-2020 | |
| Ardelyx, INC. | $77.08 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $64.30 | 2024 | Omvoh |
| Qol Medical, LLC | $54.28 | 2023 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $51.17 | 2024-2025 | Iqirvo |
| Novo Nordisk INC | $47.56 | 2023-2025 | Wegovy |
| Shionogi INC | $37.43 | 2019 | |
| Ucb, INC. | $36.96 | 2019 | |
| Alnylam Pharmaceuticals INC. | $36.46 | 2025 | Givlaari |
| Concordia Pharmaceuticals INC. | $23.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.26 | 2023 | |
| Evoke Pharma, INC. | $20.66 | 2020 | |
| Pfizer INC. | $20.22 | 2019 | |
| Napo Pharmaceuticals INC | $12.29 | 2019 | |
| Ambu INC. | $8.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tsuchiyose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.